This article is more than 5 years old. Information may no longer be current.
Top 10 stories of 2010
Click Here to Manage Email Alerts
Every year the Endocrine Today Editorial Board members
vote on what they think are the most significant stories of the past year. The
following are their selections.
Think we missed any? E-mail us at
Editor@EndocrineToday.com
and tell us your thoughts.
Aggressive BP control not effective, possibly harmful, in patients
with diabetes
Tight systolic blood pressure control in high-risk
patients with diabetes appears to be no more effective for avoiding myocardial
infarction, stroke or death when compared with standard treatment. Read more.
‘Conflict of interest’ an outdated phrase for
physician-industry relationship?
Current conflict-of-interest policies, designed in
theory to encourage transparency and ethicality in collaborative relationships
between physicians and industry, may place limits on what physicians may and
may not do regarding their involvement with activities and research funded by
industry. Read more.
Denosumab approved for treatment of postmenopausal osteoporosis
The FDA approved denosumab, an injectable treatment for
postmenopausal women with osteoporosis who are at high risk for fractures,
including those with multiple risk factors, history of fracture and those who
have failed or are intolerant to other available therapies. Read more.
FDA restricts rosiglitazone use
In a new decision this year, rosiglitazone use is now
restricted to patients with type 2 diabetes who cannot control their diabetes
with other available medications. Read more.
New propylthiouracil warnings change face of hyperthyroid treatment
in pregnancy
In 2010, the FDA added a boxed warning to
propylthiouracil to include information on reports of severe liver injury and
acute liver failure, of which some have been fatal, in both adult and pediatric
patients. Read more.
Sibutramine withdrawn from US market
Elevated cardiovascular risks in certain patients taking
sibutramine prompted the FDA to issue a recommendation against continued
prescription and use of the weight-loss drug. The agency determined that the
cardiovascular risks outweigh the “marginal benefits” associated with
sibutramine and requested that Abbott Laboratories voluntarily withdraw the
product from the US market. Read more.
Warnings released about atypical femoral fractures, bisphosphonates
link
The possible risk for atypical femoral fractures in
patients who take bisphosphonates was in the spotlight this year based on new
data and an FDA warning. Although it is not clear whether bisphosphonates are
to blame, atypical femoral fractures have been predominantly reported in
patients taking the osteoporosis drug. Read more.
Diabetes costs projected to soar to $3.4 trillion by 2020
More than 50% of Americans could have diabetes or
prediabetes by 2020, at a cost of $3.35 trillion over the next decade if
current trends continue, according to new projections. Read more.
STAR 3: Sensor-augmented insulin pump bested multiple
daily injections for glucose control
Adding a continuous blood glucose level sensor to
insulin pump therapy led to better blood glucose control compared with multiple
daily insulin injections in children and adults with uncontrolled type 1
diabetes, according to findings from the STAR 3 trial. Read more.
New dietary intake levels of calcium, vitamin D established
The Institute of Medicine now recommends no more than
600 IU of vitamin D per day for adults and as much as 800 IU per day for adults
aged 71 years and older to maintain health. Read more.
 |
Follow EndocrineToday.com on Twitter. |